Mr Mueller has stood down in order to “pursue other interests”, the company said, and will be replaced by existing Chief Financial Officer Peter Grant.
Frank Condella, Chairman, SkyePharma, thanked Mr Mueller for his “efforts” whilst at the company and was pleased to have found an “appropriate replacement” in their existing CFO.
SkyePharma, a leading speciality drug delivery company, recently announced plans to reduce its workforce at its research facility in Muttenz, Switzerland, by 20% in an attempt to generate annual savings of £1.8 million.
Mr Grant, who joined the company in November 2006 after serving as interim CEO at Voice Commerce, will retain his existing responsibility for the Group’s financials as part of his new role.
He will also continue to oversee the development of Flutiform, a fixed-dose combination treatment for asthma, and the collaboration with Mundipharma International on the inhaler – which was submitted for regulatory approval in Europe in 2010.
“Peter’s knowledge of the group, understanding of the finances, excellent track record in reducing SkyePharma’s cost base and experience of the Flutiform development and regulatory process over the past five years make him the ideal candidate to take the company forward,” commended Mr Condella.